Wockhardt USA LLC

India launches the ₹5,000 crore Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme, expected to attract ₹17,000 crore in additional R&D investment by end of 2025.

Senores Pharmaceuticals has acquired the US FDA-approved ANDA for enalapril maleate tablets in multiple dosages from Wockhardt, expanding its presence in the hypertension treatment market.

Wockhardt's novel antibiotic Zaynich, a combination of Zidebactam and Cefepime targeting multi-drug resistant Gram-negative infections, is anticipated to receive USFDA approval next year.

Wockhardt's Miqnaf (Nafithromycin) has been approved by CDSCO for treating community-acquired bacterial pneumonia (CABP) in adults, offering a new treatment option.

Wockhardt's Zaynich (zidebactam/cefepime) achieved superiority over meropenem in a Phase III trial for complicated urinary tract infections (cUTI).

• Wockhardt's drug Zaynich (WCK 5222) successfully treated a US cancer patient with infections caused by highly resistant bacteria, facilitating a transplant. • The drug effectively neutralized resistance mechanisms like IMP, NDM, and OXA-48 in Pseudomonas aeruginosa and Klebsiella pneumoniae. • Zaynich is nearing completion of Phase III trials for global registration, with potential availability in global markets by 2026. • Compassionate use of Zaynich has benefited 45 patients to date, addressing unmet needs for antibacterial drugs against superbugs.

• Several pharmaceutical and biotech companies are actively developing novel therapies for complicated urinary tract infections (cUTIs). • Spero Therapeutics' Tebipenem Pivoxil Hydrobromide is in Phase III clinical trials, representing a late-stage advancement in cUTI treatment. • Other companies like Iterum Therapeutics and Venatorx are also contributing to the cUTI therapeutics market with drugs like Sulopenem. • Emerging therapies cover various routes of administration, molecule types, and mechanisms of action, offering diverse treatment options.

India has launched Nafithromycin, its first indigenously developed macrolide antibiotic, to combat antimicrobial resistance (AMR).

Nafithromycin, India's first indigenously developed antibiotic, has been launched to combat antimicrobial resistance (AMR).

Nafithromycin, India's first indigenous antibiotic, targets drug-resistant community-acquired bacterial pneumonia (CABP) and offers a new treatment option.